Basilea announces acquisition of preclinical antibiotics program from Spexis

Allschwil, Switzerland, January 15, 2024

The rest is here:
Basilea announces acquisition of preclinical antibiotics program from Spexis

Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™

VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona LaboratoriesTM - a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMimTM.

View post:
Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™

ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants

Can provide protection for millions of immuno-compromised and elderly who are most vulnerable to COVID-19 Can provide protection for millions of immuno-compromised and elderly who are most vulnerable to COVID-19

Read the original post:
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants

XORTX Announces $2 Million Public Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES

Original post:
XORTX Announces $2 Million Public Offering

Guerbet: Financial agenda for 2024

Financial agenda for 2024

Originally posted here:
Guerbet: Financial agenda for 2024

AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

PRESS RELEASE

Read the original here:
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

GENFIT Announces 2024 Financial Calendar  

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024.

Read more from the original source:
GENFIT Announces 2024 Financial Calendar  

European Commission approves Roche’s Tecentriq SC, the EU’s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

Basel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Last year, more than 38,000 people in the EU received Tecentriq to treat different types of lung, liver, bladder and breast cancer.7 Until now, Tecentriq has been given directly into patients’ veins by IV infusion which takes approximately 30-60 minutes.6 The new subcutaneous injection will cut treatment time to approximately seven minutes, with most injections taking between four and eight minutes.6 The marketing authorisation applies to all approved indications of Tecentriq IV.7

More:
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

Go here to read the rest:
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024  

Read the rest here:
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024